Comparative Pharmacology
Head-to-head clinical analysis: XELJANZ versus XELJANZ XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XELJANZ versus XELJANZ XR.
XELJANZ vs XELJANZ XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor. Selectively inhibits JAK1 and JAK3, mediating signaling of cytokines/growth factors involved in immune response and hematopoiesis.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and TYK2, modulating cytokine signaling pathways involved in immune responses.
5 mg orally twice daily; for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. For ulcerative colitis induction, 10 mg orally twice daily for 8 weeks; maintenance at 5 mg orally twice daily.
11 mg orally once daily, with or without food, for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; for ulcerative colitis, use 5 mg twice daily if switching from immediate-release tofacitinib 5 mg twice daily.
None Documented
None Documented
Terminal half-life is approximately 3.3 hours. Twice-daily dosing maintains therapeutic concentrations.
Terminal elimination half-life is approximately 3.3 hours for the immediate-release formulation; for XELJANZ XR (extended-release), effective half-life is prolonged due to extended absorption, but terminal half-life remains ~3.3 hours. Clinical context: Twice-daily dosing for IR, once-daily for XR.
Approximately 70% of the dose is excreted in urine (30% as unchanged drug, 40% as metabolites) and 20% in feces (10% as unchanged drug).
Renal excretion accounts for approximately 70% of total clearance (30% unchanged drug, 40% as metabolites); biliary/fecal excretion accounts for approximately 30% of total clearance (metabolites).
Category C
Category C
JAK Inhibitor
JAK Inhibitor